Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Oct 29, 2022 12:30pm
143 Views
Post# 35057751

RE:Cydy pulling out of Hiv MDR

RE:Cydy pulling out of Hiv MDRAnd yet, CYDY still has a market cap nearly 2x that of THTX! This will not always be the case but it has been for far longer than I would have ever imagined possible. There is no logical justification for this but CYDY pursued retail investors and THTX did not and that likely is a big part of how this has happened and persisted for so long. It has clearly been hard to deal with THTX's chronic underperformance, even while the company has gotten better in most tangible ways, but it is even harder whenever I take a glimpse at CYDY's market cap. It is just galling.

But if something can't continue, it usually doesn't. THTX's time is likely coming and my understanding is they are making a more serious push on the retail side of the equation. Let's hope they get the results CYDY has gotten from those efforts. 

palinc2000 wrote: CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
https://seekingalpha.com/pr/18996550-cytodyn-announces-voluntary-withdrawal-of-bla-for-hiv-mdr-due-to-cro-data-management-issues


<< Previous
Bullboard Posts
Next >>